---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273373"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:41:29.167115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected

## Summary
- Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.
- Cash and equivalents $561.6M, including $195M upfront from Novo Nordisk and $12.5M from Vertex; runway into 2029.
- Selected SEP-479 as oral PTH1R agonist development candidate for hypoparathyroidism; Phase 1 expected H1 2026.
- SEP-631 Phase 1 ongoing for mast cell diseases; initial data expected H1 2026.
- Appointed Keith Gottesdiener, M.D., to Board as chair of R&D Committee.

## SEC filing metadata
- accession: 0001193125-25-273373
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/0001193125-25-273373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/sepn-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273373
- JSON: https://secwatch.observer/filing/0001193125-25-273373.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.